Clinical Trial Update: Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial evaluates the combination of nintedanib and azacitidine in adults with HOX gene overexpression acute myeloid leukemia that is relaps…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Nintedanib (nintedanib)

Snippet

Sponsor: Northwestern University | Conditions: Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A, Fibroblast Growth Factor Basic Form Measurement | Phase 1 | Status: ACTIVE_NOT_RECRUITING